接受钠-葡萄糖协同转运蛋白2抑制剂治疗的骨髓纤维化患者血红蛋白水平的偶然变化。 - Suppr

Suppr

超能文献

Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors.

作者信息

Aperna Fnu, Alsugair Ali K, Fathima Saubia, Tefferi Ayalew, Gangat Naseema

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN.

出版信息

Haematologica. 2025 Apr 1;110(4):1034-1037. doi: 10.3324/haematol.2024.286867. Epub 2024 Nov 28.

DOI:10.3324/haematol.2024.286867

PMID:39605215

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11959260/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4759/11959260/806b05e99c17/1101034.fig1.jpg

相似文献

Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors.接受钠-葡萄糖协同转运蛋白2抑制剂治疗的骨髓纤维化患者血红蛋白水平的偶然变化。

Haematologica. 2025 Apr 1;110(4):1034-1037. doi: 10.3324/haematol.2024.286867. Epub 2024 Nov 28.

Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂可抑制新诊断2型糖尿病患者的心钠素分泌。

Diabet Med. 2016 Dec;33(12):1732-1736. doi: 10.1111/dme.13107. Epub 2016 May 26.

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.钠-葡萄糖共转运蛋白 2 抑制剂对 2 型糖尿病合并非酒精性脂肪性肝病患者肝脂肪量和身体成分的影响。

Clin Drug Investig. 2019 Jul;39(7):631-641. doi: 10.1007/s40261-019-00785-6.

Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.2型钠-葡萄糖协同转运蛋白2抑制剂可降低2型糖尿病肾病患者的夜间家庭血压。

Diab Vasc Dis Res. 2017 May;14(3):258-261. doi: 10.1177/1479164117690299. Epub 2017 Feb 1.

Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study.高尿酸血症患者钠-葡萄糖共转运蛋白 2 抑制剂降糖效果的临床预测因素：一项回顾性描述性观察研究。

Biol Pharm Bull. 2020;43(5):782-787. doi: 10.1248/bpb.b19-00785.

Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.2型糖尿病患者对新型抗糖尿病药物（二肽基肽酶-4抑制剂、钠-葡萄糖协同转运蛋白-2抑制剂和胰高血糖素样肽-1受体激动剂）治疗的持久性：一项全国性队列研究。

Diabetes Ther. 2018 Oct;9(5):2133-2141. doi: 10.1007/s13300-018-0483-4. Epub 2018 Aug 17.

Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病重症监护病房患者中的应用：一项初步的病例对照研究。

Crit Care. 2023 May 16;27(1):189. doi: 10.1186/s13054-023-04481-y.

Retrospective Analysis of Factors Influencing the Hemoglobin Level-increasing Effect of Sodium-glucose Co-transporter-2 Inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂对血红蛋白水平影响的回顾性分析。

In Vivo. 2024 Nov-Dec;38(6):2767-2773. doi: 10.21873/invivo.13756.

A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.不同钠-葡萄糖协同转运蛋白 2（SGLT-2）抑制剂在 2 型糖尿病患者管理中的疗效和安全性的对比研究。

J Assoc Physicians India. 2022 Jun;70(6):11-12. doi: 10.5005/japi-11001-0001.

A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'.一类用于治疗2型糖尿病的新型药物：钠-葡萄糖协同转运蛋白抑制剂：“糖利尿药”

Diabetes Metab Syndr. 2012 Oct-Dec;6(4):224-8. doi: 10.1016/j.dsx.2012.08.003. Epub 2012 Oct 16.

本文引用的文献

The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: State-of-the-Art Review.钠-葡萄糖协同转运蛋白2抑制剂的心脏保护和抗癌作用：最新综述

JACC CardioOncol. 2024 Mar 12;6(2):159-182. doi: 10.1016/j.jaccao.2024.01.007. eCollection 2024 Apr.

Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.达格列净与慢性肾脏病患者贫血

NEJM Evid. 2023 Jun;2(6):EVIDoa2300049. doi: 10.1056/EVIDoa2300049. Epub 2023 May 19.

Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: Impact on hemoglobin/hematocrit levels and outcomes among 11 consecutive patients.钠-葡萄糖协同转运蛋白2抑制剂治疗原发性血小板增多症：对11例连续患者血红蛋白/血细胞比容水平及预后的影响

Am J Hematol. 2023 Nov;98(11):E298-E300. doi: 10.1002/ajh.27048. Epub 2023 Aug 8.

Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases.钠-葡萄糖协同转运蛋白2抑制剂治疗与JAK2突变型骨髓增殖性肿瘤的暴露：梅奥诊所连续9例病例系列

Am J Hematol. 2023 Oct;98(10):E276-E280. doi: 10.1002/ajh.27034. Epub 2023 Jul 20.

Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology.钠-葡萄糖协同转运蛋白2抑制剂的使用与红细胞增多症：风险评估及血液科转诊需求

Nephrol Dial Transplant. 2023 Nov 30;38(12):2670-2672. doi: 10.1093/ndt/gfad171.

Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂增强肾脏和肝脏促红细胞生成素合成的机制。

Eur Heart J. 2023 Dec 21;44(48):5027-5035. doi: 10.1093/eurheartj/ehad235.

Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases.100例连续病例中钠-葡萄糖协同转运蛋白2抑制剂的使用与JAK2未突变红细胞增多症

Am J Hematol. 2023 Jul;98(7):E165-E167. doi: 10.1002/ajh.26933. Epub 2023 Apr 19.

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.原发性骨髓纤维化：2023年诊断、风险分层及管理的最新进展

Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6.

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。

Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.

Gliflozins in the Management of Cardiovascular Disease.格列净类药物在心血管疾病管理中的应用

N Engl J Med. 2022 May 26;386(21):2024-2034. doi: 10.1056/NEJMra2115011.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验